CEO Blog

July 24, 2014

British Prime Minister David Cameron: Antibiotic Resistance Threatens to Plunge the World Back to the Dark Ages of Medicine

British Prime Minister David Cameron warned earlier this month that the world is in danger of being thrust back into the dark ages of medicine unless action is taken to tackle to growing threat of antibiotic resistance. Cameron’s comments followed those last year from Dame Sally Davies, Britain’s chief medical officer, who warned Parliament that the rise in drug-resistant bacteria raised the prospect of a civil emergency. She described an “apocalyptic” scenario in which people undergoing simple operations in 20 years die of routine infections.

Read More…

June 12, 2014

RUTHIGEN CLEARED TO INITIATE HUMAN CLINICAL TRIALS FOR RUT58-60 IN THE U.S.

SANTA ROSA, Calif. — (June 12, 2014) — Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application without a clinical hold to begin human clinical testing of RUT58-60. Read More…

June 3, 2014

CEO’s Letter to Shareholders

On June 3, 2014, Ruthigen filed a letter to its shareholders on Form 8-K with the U.S. Security and Exchange Commission. Click here to view the letter

March 31, 2014

Ruthigen Corporate Presentation – March 2014